Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Reducing CAR-T toxicity

Yu-Tzu Tai • 15 Sep 2019
IMW 2019
Multiple Myeloma CAR-T

Dr. Yu-Tzu Tai, PhD of the Dana-Farber Cancer Institute, Boston, MA describes how CAR-T cells may be used to reduce the toxic effects of therapy and the promise of new antibody-drug conjugates. Recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

More from Yu-Tzu Tai

3:28
Using γ-secretase inhibitors to potentiate the efficacy of BCMA-targeted therapy in multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
5:22
Novel target antigens to improve the efficacy of immunotherapeutics in multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
1:35
Rationale for using immunotherapies in the frontline treatment of multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
2:58
BiTEs for MM
Yu-Tzu Tai • 15 Sep 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals